Majalah Farmasi dan Farmakologi - 2026

Guidelines for Authors

Majalah Farmasi dan Farmakologi · 2026 · aligned with MFF Manuscript Template 2026 (version 1.4)

WHAT THIS GUIDELINE COVERS

This document states what Majalah Farmasi dan Farmakologi (MFF) requires of a manuscript and how a submission is handled. The section order, the type sizes and the citation style given here are the ones built into the 2026 manuscript template; where this guideline and the template appear to differ, the template is authoritative and the editorial office should be informed. The manuscript is one of four documents: the Declarations and Statements form, the Copyright Transfer Agreement and the cover letter are separate files and are never appended to the manuscript. Policies that are not part of the template, such as the article processing charge and the peer review process, are reproduced from the journal website. A manuscript that does not follow this guideline may be returned without review.

DOWNLOAD THE 2026 DOCUMENTS

Click a file name; the file downloads to your computer. The same four files are listed in Table 8 at the end of this page.

MFF_Template_for_Authors_2026.docx

Manuscript template (Word). The article is written inside this file.

MFF_Author_Guidelines_2026_EN.pdf

Author guidelines (PDF). The page you are reading, as a printable file.

MFF_Declarations_and_Statements_2026.docx

Declarations and Statements form (Word), sections 1 to 6, signed by the corresponding author.

MFF_Copyright_Transfer_Agreement.docx

Copyright Transfer Agreement (Word), signed by the corresponding author on behalf of all authors.

Contents

  1. 1. Focus and scope
  2. 2. Article types
  3. 3. Manuscript preparation
  4. 4. Results and discussion, tables and figures
  5. 5. Supplementary data
  6. 6. References and citation style
  7. 7. Declarations and accompanying documents
  8. 8. Ethics, originality and plagiarism
  9. 9. Copyright, licence and open access
  10. 10. Article processing charge
  11. 11. Peer review process
  12. 12. How to submit and editorial office

1. Focus and Scope

MFF focuses on the results of research and of literature review in the multi fields of pharmacy, especially the pharmacology of Indonesian natural products. The topics may include, but are not limited to, pharmaceutics, pharmaceutical chemistry, pharmaceutical technology, pharmacology, pharmacognosy and phytochemistry, pharmaceutical microbiology and biotechnology, social-economy pharmacy, and clinical pharmacy. A manuscript outside this scope is rejected by the editor without review.

The journal is published by the Faculty of Pharmacy, Universitas Hasanuddin, Makassar, Indonesia, is accredited SINTA 3 by the Directorate General of Higher Education (DGHE) DIKTI No. 36/E/KPT/2019, and appears three times a year, in April, August and December.

2. Article Types

From Volume 25 the journal accepts the article types listed in Table 1. The type must be stated on the first line of the manuscript. The template provides the label line “ORIGINAL ARTICLE / REVIEW ARTICLE”, of which only one is kept and the other is deleted.

Table 1. Article types accepted by MFF.

Article type Content
Original article Primary experimental, clinical or observational data that have not been published elsewhere.
Review
  • Systematic Review – A defined question answered with a reproducible search strategy and explicit selection criteria.
  • Narrative review – A critical narrative synthesis of the literature on a defined topic.
  • Other type of Review article (qualified version will be assessed through editorial stage)

Note: the length limits are set by the journal website. A submission contains no fewer than 2,000 words and does not exceed 10 A4 pages including figures and tables, excluding appendices.

3. Manuscript Preparation

Language and file

Manuscripts are written in Bahasa Indonesia or in English, in clear, correct and consistent language, and are submitted as a Microsoft Word file (.doc or .docx) prepared with the 2026 MFF manuscript template. Do not convert the manuscript to PDF and do not rebuild the layout: replace the example content with your own and keep the typography of the template. No section of the template is deleted except the example text that it contains, and no section is added beyond the nine numbered sections except at the request of the editor.

Typography

The type sizes in Table 2 are the ones set in the template and are not changed by the author. Paragraphs are single spaced and are justified; in the Introduction, the Materials and Methods and the Results and Discussion the template sets no first-line indentation, so each paragraph starts flush with the left edge of the column.

Table 2. Type sizes and alignment set in the template.

Element Face and size Other settings
Article type label Calibri Bold 12 pt, black First line of the manuscript; one label only
Title Calibri Bold 22 pt, dark blue Title case, preferably not more than 20 words
Author names Calibri Bold 11 pt Superscript affiliation letters
Affiliation Calibri 10 pt Department, faculty, university, country, then the e-mail address
Corresponding author Calibri 10 pt Marked with an asterisk
Abstract Calibri 10 pt inside a grey box Single spaced, no indentation, not more than 250 words
Keywords Calibri 10 pt 3-5 keywords, separated by commas, closed with a full stop
Section heading Calibri Bold 13 pt, blue Numbered 1., 2., 3. and so on
Sub-heading Calibri Light 12 pt, blue Numbered 2.1., 2.2., 2.2.1. up to four levels
Body text Calibri Light 12 pt, black Single spaced, justified, no indentation
Table caption Calibri Light 11 pt Above the table, label bold
Table content Calibri Light 9 pt Head row bold
Table, figure and supplementary note Calibri Light 8 pt Below the table, figure or list
Figure caption Calibri Light 11 pt Below the figure, label bold
Reference list Calibri Light 10 pt Numbered, hanging indent
In-text citation 8 pt superscript [1], [2,3], [4-6]

Title, authors and affiliations

The title is typed in title case and preferably does not exceed 20 words. Plant and animal names are italicised; abbreviations that are not universally known are written out. Author names are given as first name and surname in full, without academic degrees, and each carries a superscript letter that links it to its affiliation. Each affiliation line gives the department, the faculty, the university and the country, followed by the e-mail address of the author. The corresponding author is marked with an asterisk and is the only addressee for correspondence during review and after publication.

Abstract and keywords

The abstract is one paragraph of not more than 250 words, typed in Calibri 10 pt inside the grey box of the template, single spaced and without indentation. It states briefly the background, the objective, the method, the principal quantitative results with their statistical significance, and the conclusion. No citation, figure, table or undefined abbreviation is used in the abstract, and every abbreviation is written out at first mention. Findings are stated as the article's results and are not left as open questions, and the conclusion answers the objective. Three to five keywords or phrases are placed under the abstract, separated by commas and closed with a full stop.

Section order

The manuscript follows the order in Table 3, and the numbering is typed as shown. Sections 7 and 9 are required in every manuscript, section 8 is required when supplementary material is supplied, and sections 5 and 6 are used only where they apply. Sections 1 to 4 carry no bullet points; the running text of the article is written in paragraphs throughout.

Table 3. Required section order of the 2026 template.

Section Content
1. Introduction The issue to be discussed, an adequate background, a short review of previous work and its limitations, the gap, the novelty, and the objective at the end of the section. No figure or table.
2. Materials and Methods Study design, materials and equipment, procedures and statistical analysis, in enough detail to be reproduced. Sub-sections may go to the fourth level (2.2.1.).
3. Results and Discussion Continuous prose, without sub-sections and without bullet points, or the results alone where the discussion is separated (see 4.1). Every value is reported in a sentence with its measure of dispersion, and every table and figure is cited in the order in which it appears.
4. Conclusion The objective answered in one or more paragraphs, without recommendation, citation, new data or reference to a table or figure. Where the discussion was separated, the discussion takes heading 4 and the following sections are renumbered.
5. Acknowledgments (optional) The people, institutions or facilities that supported the work but do not meet the authorship criteria, with the form of the support, in a sentence and not in a list.
6. Funding (optional) The grant name, funding agency and grant number, or the statement that the research received no external funding, and any role of the sponsor.
7. Data Availability Statement (required) Where the data supporting the findings can be obtained, in one or two sentences, in one of the forms printed in the template.
8. Supplementary Data (required when applicable) What the supplementary files contain and the list of files in Table 2 of the manuscript, or the statement that no supplementary data are available.
9. References Numbered in the order of citation, in the style of section 6 of this guideline.

What the manuscript does not contain

The 2026 template no longer carries a conflict of interest section or an author contribution section. Those statements, together with the authorship declaration, the funding declaration, the ethics approval and the generative AI declaration, are made in the Declarations and Statements form, which is a separate document and is not pasted into the manuscript (section 7 of this guideline). The funding statement and the data availability statement remain in the manuscript, because they belong to the published article.

4. Results and Discussion, Tables and Figures

Two acceptable writing styles

The results and the discussion are written in one of two styles, and the choice is stated neither in the manuscript nor in the submission form; it is simply followed consistently. In the combined style the whole section is written as continuous prose under main heading 3, without sub-sections and without bullet points. In the separated style the results are placed under main heading 3 with sub-sections of their own (3.1., 3.2., and so on) where they help the reader, the discussion is placed under main heading 4 without sub-sections and without bullet points, and the sections that follow are renumbered accordingly, so that the references become section 10. Either style respects the rule that no bullet point, no numbered list and no table substitutes for a sentence: interpretation is integrated with the findings, comparison with previous work is supported by a citation, and the limitations of the study close with their implications.

Tables

A table is placed on the proper area inside the results and discussion and is cited in the text as (Table 1) in the order of its appearance; the placement and the numbering of tables and figures are not changed at proof stage. The caption is typed above the table in Calibri Light 11 pt and its label is bold. The table uses the open model: no vertical rule and no rule between the rows of the body, with rules only above and below the head row and below the last row. The head row is bold and the body is typed in Calibri Light 9 pt, single spaced. Units and abbreviations are explained either in the note below the table or in the head row in brackets, and the note is typed in Calibri Light 8 pt.

Where the content of a table is longer than one margin page, the table may be placed on a page of its own, in portrait or landscape orientation, with the caption above it and the note below it, and it is still cited in the text in the usual way. Data that are too large to be printed in any form are moved to the supplementary data (section 5).

Figures

A figure is cited in the text as (Figure 1) in the order of its appearance and has a good resolution, at least 300 dpi, with a maximum width of 7.6 cm. All components of a figure, including its labels and arrows, form one complete image file and are never added as separate text boxes. The caption is typed below the figure in Calibri Light 11 pt with a bold label, and the note follows in Calibri Light 8 pt. The text states the main finding and the authors' interpretation rather than rewriting the content of the table or the figure, and where colour is needed in print this is stated in the cover letter.

5. Supplementary Data

What counts as supplementary data

Supplementary data are material that supports the article but is not essential to its interpretation: large data tables, questionnaires and instrument validation sheets, calibration curves, spectra and chromatograms, detailed protocols, and source code. The material is not typeset by the journal, is published as supplied, and appears online with the article. Section 8 of the manuscript states what the files contain and gives the list of files in Table 2 of the manuscript.

How the files are prepared

Each file is uploaded separately at submission and is never pasted into the manuscript. The files are named in the order of their citation — Supplementary Table 1, Supplementary Figure 1, Supplementary File 1 — and each is cited at least once in the main text, in the order in which it is named. Each file opens with a title page carrying the article title, the author names, the item number and a short caption, so that a file opened on its own can still be identified. The file name given in the submission form must match the description in the list, and a file that is described but not uploaded, or uploaded but not described, delays the manuscript at the technical check.

Table 4. The list of supplementary files, as it appears in section 8 of the manuscript.

Item File name Description and content
Supplementary Table 1 Sup_Table_1.xlsx Full data set behind Table 1, with the units and the number of replicates stated in the head row.
Supplementary Figure 1 Sup_Fig_1.tif Additional micrographs at higher magnification; one complete image file at 300 dpi or more.
Supplementary File 1 Sup_File_1.pdf Questionnaire, instrument validation sheet or detailed protocol.

Note: add or delete rows to match the material actually supplied. The file name in the submission form must match this list.

Where there is nothing to supply

Where the article has no supplementary material, section 8 of the manuscript is reduced to the single sentence “Supplementary data are not available for this article” and the rest of the section is deleted. An empty list, a list of files that do not exist, and the sentence above followed by a list are equally rejected at the technical check. Supplementary material that contains images of human participants, identifiable clinical data or animal procedures is covered by the ethics approval reported in section 2 of the manuscript, and any further permission that is required is stated in the description of the file.

6. References and Citation Style

MFF uses the Vancouver style. In-text citations are Arabic numerals in square brackets set as 8 pt superscripts, in the order of first appearance: one source[1], two sources[2,3], and a range[4-6]. The reference list is numbered in the same order and is typed in Calibri Light 10 pt. At least ten sources are required, and at least 75% of them should be taken from publications of the last ten years. Every source in the list is cited in the text and every citation in the text appears in the list. Table 5 shows the format for the most common source types; the full set of examples is printed at the end of the template under Notes on Citation.

Table 5. Reference format for the most common source types.

Source type Format and example
Journal article Author AA, Author BB, Author CC. Title of the article. Journal Abbrev. Year;Volume(Issue):first-last. DOI. Example: Subehan, Kadota S, Tezuka Y. In Vitro Mechanism-Based Inactivation of Cytochrome P450 3A4 by a New Constituent of Cinnamomum burmanii. Planta Med. 2008;74(12):1474-1480. DOI:10.1005/s-2008-1081351
Book with a single author Author AA. Title. Edition. Place: Publisher; Year. Example: Rang HP, Dale MM, Ritter JM, Moore PK. Pharmacology. 5th ed. Edinburgh: Churchill Livingstone; 2003.
Book with editors Editor AA, Editor BB, editors. Title. Edition. Place: Publisher; Year. Example: Beers MH, Porter RS, Jones TV, Kaplan JL, Berkwits M, editors. The Merck manual of diagnosis and therapy. 18th ed. Whitehouse Station (NJ): Merck Research Laboratories; 2006.
Chapter in an edited book Author AA. Title of the chapter. In: Editor AA, Editor BB, editors. Title of the book. Edition. Place: Publisher; Year. Example: Glennon RA, Dukat M. Serotonin receptors and drugs affecting serotonergic neurotransmission. In: Williams DA, Lemke TL, editors. Foye's principles of medicinal chemistry. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2002.
Internet material Organisation. Title of the page [internet]. Place: Publisher; Year. Available from: URL

Note: a supplementary item is cited as (Supplementary Table 1) and is not given a number in the reference list.

A reference manager may be used, but its output is checked by hand: capitalisation, a missing volume or issue number and a truncated author list are the commonest errors. Material in press needs a letter of acceptance; personal communications and unpublished observations are cited in the text in parentheses and do not appear in the reference list.

7. Declarations and Accompanying Documents

The manuscript is one of four documents. Three further files are separate documents with their own signature blocks, are uploaded with the submission, and are never appended to the manuscript or pasted into it. Table 6 lists them with the signature that each requires.

Table 6. Documents that accompany every submission.

Document What it contains Who signs
Manuscript The article itself, in the 2026 template, with sections 1 to 9. No signature in the file
Declarations and Statements form (sections 1 to 6) Authorship and originality, conflict of interest, author contribution, funding, ethics approval and generative AI declaration. The corresponding author, on behalf of all authors
Copyright Transfer Agreement The transfer of copyright to the Faculty of Pharmacy, Universitas Hasanuddin, together with the originality warranty. The corresponding author, on behalf of all authors
Cover letter The novelty of the work and its importance, addressed to the Editor-in-Chief. The corresponding author

Declarations and Statements form

The form is filled in at the keyboard before signing; a declaration is never left blank, and a statement that does not apply is worded as the form shows rather than deleted. Conflict of interest is declared for every author, including any personal circumstance or interest that may be perceived as inappropriately influencing the representation or interpretation of the results, and the statement “The authors declare no conflict of interest” is used where there is nothing to declare. The author contribution paragraph specifies the individual contribution of each author, in the form “X.X. and Y.Y. conceived and designed the experiments; X.X. performed the experiments; Y.Y. wrote the paper”. Any use of generative artificial intelligence in preparing the manuscript is declared by naming each tool and the purpose for which it was used; AI used as part of the research method is described in the Materials and Methods of the manuscript, and the authors remain fully responsible for the accuracy of every reference, chemical name, dose and statistical value.

Copyright Transfer Agreement

The agreement is signed by the corresponding author on behalf of all co-authors and transfers to the Faculty of Pharmacy, Universitas Hasanuddin, the copyright in the article, including the exclusive right to reproduce and distribute it, if and when the article is accepted. It also warrants that the article is original, that it has not been published in the same form elsewhere and is not under consideration elsewhere, and that permission has been obtained for material taken from other sources. After the signed agreement has been submitted, no change of authorship or of the order of the authors is accepted.

8. Ethics, Originality and Plagiarism

By submitting a manuscript the authors declare that the work is their own, that it has not been published in the same form elsewhere, and that it is not under consideration by another publication. All submissions are screened for plagiarism with Turnitin. A manuscript in which plagiarism is detected during review or in the editorial process is rejected immediately; where plagiarism is proven after publication the article is retracted and an announcement is published. Depending on the seriousness of the case the journal may also blacklist the authors from future publication and notify the authors' funding agencies, the authors' institutions and the authors of the plagiarised work.

The journal follows the COPE flowcharts for suspected plagiarism in a submitted manuscript and in a published manuscript, and the COPE Retraction Guidelines. Studies involving human participants, animals or biological material state the name of the approving committee and the approval number within the Materials and Methods, and the same approval is repeated in section 5 of the Declarations and Statements form.

9. Copyright, Licence and Open Access

The journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. Published articles are distributed under the CC BY 4.0 licence shown in the footer of the template, which permits use, distribution and reproduction in any medium provided the original work is properly cited. The copyright of the article is held by the Faculty of Pharmacy, Universitas Hasanuddin, under the terms of the Copyright Transfer Agreement described in section 7.

10. Article Processing Charge

A publication fee of IDR 500,000 is charged to an accepted manuscript. The charge arises only after acceptance and is settled before the article is published. No charge is made at submission and no charge is made for a rejected manuscript. Questions about invoicing, a purchase order or a receipt for reimbursement are addressed to the editorial office.

11. Peer Review Process

Manuscripts are transmitted through the journal website. The editorial board screens all incoming submissions and may reject a manuscript without further review, or review and reject it where it does not meet the standards of the journal. A paper that passes screening is evaluated by the editor for contribution, originality, relevance and presentation, and is then assigned to up to two reviewers in a single-blind review, in which the reviewers know the identity of the authors and the authors do not know the identity of the reviewers. The process takes 30 to 60 days.

  1. Editorial screening: scope, completeness and conformity with this guideline.
  2. Similarity check: plagiarism detection with Turnitin before a reviewer is assigned.
  3. Assignment: up to two reviewers, single blind.
  4. Timeline: 30 to 60 days from assignment.
  5. Decision: accept, minor or major revision, or reject.
  6. Revision: a revised manuscript is returned with a point-by-point response to each comment within the deadline in the decision letter.

12. How to Submit and Editorial Office

A submission is made through the journal website at https://journal.unhas.ac.id/index.php/mff. A first-time author registers an account, completes the profile with the affiliation and postal address, and starts a new submission from the author dashboard. Table 7 lists the files and items that are required at submission.

Table 7. Files and items required at submission.

Item Requirement
Manuscript Word file (.doc or .docx) prepared with the 2026 template, containing the keywords, all figures with their captions, all tables with their titles and notes, the funding statement, the data availability statement and, where applicable, the supplementary data section.
Declarations and Statements form Downloaded from the journal website, completed and signed by the corresponding author, uploaded as a separate file.
Copyright Transfer Agreement Downloaded from the journal website, signed by the corresponding author, uploaded as a separate file.
Supplementary files Uploaded separately, one file per item, named as the list in section 8 of the manuscript gives them.
Corresponding author One author designated, with an e-mail address and a full postal address.

And before pressing submit

  1. The manuscript has been spell-checked and grammar checked.
  2. All references in the list are cited in the text, and vice versa.
  3. Permission has been obtained for the use of copyrighted material from other sources, including the internet.
  4. The Declarations and Statements form and the Copyright Transfer Agreement are signed and attached.
  5. Every supplementary file listed in section 8 of the manuscript is uploaded, and its file name matches the list.
  6. The journal policies detailed in this guideline have been reviewed, and the publication fee of IDR 500,000 for the accepted manuscript is understood.

Editorial office

Journal Majalah Farmasi dan Farmakologi (MFF)
Publisher Faculty of Pharmacy, Universitas Hasanuddin
Address Gedung Fakultas Farmasi, Universitas Hasanuddin, Jl. Perintis Kemerdekaan KM.10, Kampus Unhas Tamalanrea, Makassar, Sulawesi Selatan 90245, Indonesia
E-mail andiarjuna@unhas.ac.id
Website https://journal.unhas.ac.id/index.php/mff
Identifiers p-ISSN 1410-7031 | e-ISSN 2655-6715 | SINTA 3 (36/E/KPT/2019) | CC BY 4.0

Submission checklist

The declarations below are confirmed in the submission system. A submission that fails any of them may be returned without review.

  • ☐ 1. I hereby declare that this submission is my own work.
  • ☐ 2. I hereby state that this manuscript has no plagiarism matter.
  • ☐ 3. I declare the submission has no potential conflict of interest.
  • ☐ 4. I hereby state that this manuscript has never been previously published in any other scientific publication and is not being under the reviewing process of any other scientific publication.
  • ☐ 5. The submitted manuscript contains no fewer than 2,000 words and does not exceed 10 A4 pages including figures and tables, without any appendices.
  • ☐ 6. The submitted manuscript has been written using Microsoft Word (.doc/.docx) with the 2026 MFF template.
  • ☐ 7. The manuscript cites at least ten sources, at least 75% of them published within the last ten years.
  • ☐ 8. The Declarations and Statements form and the Copyright Transfer Agreement are signed by the corresponding author and attached to the submission.

The 2026 document set

Four documents are used together, and each exists in an English and an Indonesian version. The guideline is the document you are reading; the other three are downloaded from the journal website at submission.

Table 8. Documents of the MFF 2026 submission set.

Document Available file
Manuscript template MFF_Template_for_Authors_2026.docx
Author guidelines MFF_Author_Guidelines_2026_EN.PDF (this document)
Declarations and Statements form MFF_Declarations_and_Statements_2026.docx
Copyright Transfer Agreement MFF_Copyright_Transfer_Agreement.docx

Note: the file names are the ones used on the journal website; a submission that uses another version of a document is asked to replace it.


Disclaimer. The author(s) of each article appearing in this journal is/are solely responsible for the content thereof; neither Majalah Farmasi dan Farmakologi nor its editors or publisher or anyone else involved in creating, producing, or distribution assumes any liability or responsibility for the accuracy, completeness, or usefulness of any information provided in the journal, nor shall they be liable for any direct, indirect, incidental, special, consequential or punitive damages arising out of the use of Majalah Farmasi dan Farmakologi.

Privacy statement. The names and e-mail addresses entered in this journal site will be used exclusively for the stated purposes of this journal and may not be made available for any other purpose or to any other party.